FDA approves Cinqair to treat severe asthma – FDA.gov


Medscape

FDA approves Cinqair to treat severe asthma
FDA.gov
The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair is approved for patients who have a history of …
Reslizumab (Cinqair) Approved to Treat Severe AsthmaMedscape
FDA Approves Reslizumab for Adults With Severe AsthmaMedPage Today
FDA clears Teva's asthma med CinqairSeeking Alpha
Monthly Prescribing Reference (registration)
all 25 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.